Earlier this month, the FDA approved an entirely new family of drugs, one so powerful that it could put CRISPR-based gene therapy to shame. Backed by two decades of research and a Nobel Prize, these drugs have the ability to cure inherited diseases—and do so without actually needing to edit the delicate genome.
The green-lit therapy is patisiran, a drug ten years in the making by the Cambridge-based Alnylam for genetic nerve damage. But in this rare case, the nature of the drug is perhaps more significant: patisiran is based on a technology called RNA interference, or RNAi, which allows doctors to silence genes that aren’t properly functioning.
Patisiran is just the tip of the iceberg. In theory, RNAi has the potential to cure any disease caused by “bad” proteins, such as stroke, Alzheimer’s, high cholesterol, or other neurodegenerative disorders. The potential is so grand that scientists have long dubbed the technology a way to “drug the undruggable.”
“This approval is part of a broader wave of advances that allow us to treat disease by actually targeting the root cause, enabling us to arrest or reverse a condition, rather than only being able to slow its progression or treat its symptoms,” said FDA commissioner Scott Gottlieb in a press release. “New technologies like RNA inhibitors, that alter the genetic drivers of a disease, have the potential to transform medicine, so we can better confront and even cure debilitating illnesses.”
With other RNA-based therapies hurtling down the drug development pipeline, it’s likely we’ll be seeing more of these drugs soon. Here’s what you need to know.
Image Credit: Shutterstock
News This Week
Frank Boehm: Publication of our new paper “Human Brain/Cloud Interface” in Frontiers in Neuroscience
Contributors: Nuno R. B. Martins, Amara Angelica, Yuriy Svidinenko, Frank J. Boehm, Ioan Opris, Mikhail A. Lebedev, Melanie Swan, Steven A. Garan, Jeffrey V. Rosenfeld, Tad Hogg, Robert A. Freitas Jr. et al Excerpt [...]
Abstract The progressive growth in nanotechnology approaches to diagnostics and therapeutics, especially for cancer, necessitates training physicians in nanoethics. This article explains why it is critical for medical education to include instruction in [...]
The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. In May, an elderly man was admitted to the Brooklyn branch of Mount Sinai Hospital for abdominal surgery. A [...]
In a collaboration between the U.S. Department of Energy's Ames Laboratory and Northeastern University, scientists have developed a model for predicting the shape of metal nanocrystals or "islands" sandwiched between or below two-dimensional (2D) [...]
Should we be prepared to change the population composition of a species in order to wipe out a disease that is a terrible burden to mankind? During a well-attended working breakfast organised by the [...]
A new study led by Massachusetts General Hospital (MGH) investigators finds that radiation therapy may increase the uptake of therapeutic nanoparticles by glioblastomas, raising the possibility of using both growth-factor-targeted and immune-system-based therapies against [...]
Taking a cue from biological cells, researchers from MIT, Columbia University, and elsewhere have developed computationally simple robots that connect in large groups to move around, transport objects, and complete other tasks. This [...]
Nearly a third of physicians will be sued at least once in their careers — most commonly for an error in diagnosis. Medical errors are also the third-leading cause of death in the United [...]
Inventors and scientists have been continuously working towards reducing the size of technological components. Room-sized computers to laptops that are slimmer than a pane of glass? It’s done. Huge bulky telephones to smartphones that [...]
You have witnessed a variety of nano-devices that were designed for tasks including delivering medicines within the body. All of them used to move in a variety of ways. However, the latest nano-device is [...]
Netra Rajesh is an undergraduate Engineering Science student specializing in Biomedical Systems Engineering. She is currently on her Professional Experience Year (PEY) at the Massachusetts Institute of Technology where her research lies at the [...]